Fig. 2
18F-FDG PET/CT and 99mTc-NM-02 SPECT/CT of brain (patient BR023) and bone (patient BR015) metastases at 1 h post-injection. Patient BR023 was initially diagnosed with HER2-positive breast cancer on the right side (HER2 IHC 3+) with a clinical stage of T3N3M1. Metastases were found in the lymph node, bone, liver, and brain. This patient had undergone treatment with four cycles of trastuzumab–pertuzumab–docetaxel before imaging. 18F-FDG and 99mTc-NM-02 showed low-level uptake in all lesions except brain metastases. Patient BR015 was initially diagnosed with HER2-negative breast cancer on the left side (HER2 IHC 0) with a clinical stage of T2N3M1. Metastases were found in the lymph node and bone. Compared to 18F-FDG PET/CT, 99mTc-NM-02 SPECT/CT had a high uptake in more lesions, suggesting potential HER2 positivity